Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 315

1.

Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs.

Zhou J, Yun EJ, Chen W, Ding Y, Wu K, Wang B, Ding C, Hernandez E, Santoyo J, Pong RC, Chen H, He D, Zhou J, Hsieh JT.

Cell Death Dis. 2017 Mar 23;8(3):e2701. doi: 10.1038/cddis.2017.121.

PMID:
28333136
2.

Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer.

Miao L, Yang L, Li R, Nava Rodrigues D, Crespo M, Hsieh JT, Tilley WD, de Bono JS, Selth LA, Raj GV.

Cancer Res. 2017 Mar 16. pii: canres.2169.2016. doi: 10.1158/0008-5472.CAN-16-2169. [Epub ahead of print]

PMID:
28302679
3.

RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.

Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng J, Fan J, Wang X, Yue Y, Wu S, Hsieh JT, He D, Wu K.

Cell Death Dis. 2017 Feb 9;8(2):e2600. doi: 10.1038/cddis.2017.9.

PMID:
28182001
4.

Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.

Lin LC, Gao AC, Lai CH, Hsieh JT, Lin H.

Cancer Lett. 2017 Apr 10;391:74-82. doi: 10.1016/j.canlet.2017.01.018. Epub 2017 Jan 18.

PMID:
28109910
5.

Sensitization of Radioresistant Prostate Cancer Cells by Resveratrol Isolated from Arachis hypogaea Stems.

Chen YA, Lien HM, Kao MC, Lo UG, Lin LC, Lin CJ, Chang SJ, Chen CC, Hsieh JT, Lin H, Tang CH, Lai CH.

PLoS One. 2017 Jan 12;12(1):e0169204. doi: 10.1371/journal.pone.0169204. eCollection 2017.

6.

Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.

Xie Z, Su Y, Kim GB, Selvi E, Ma C, Aragon-Sanabria V, Hsieh JT, Dong C, Yang J.

Small. 2017 Mar;13(10). doi: 10.1002/smll.201603121. Epub 2016 Dec 27.

PMID:
28026115
7.

Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth.

Huang PH, Chen MC, Peng YT, Kao WH, Chang CH, Wang YC, Lai CH, Hsieh JT, Wang JH, Lee YT, Lin E, Yue CH, Wang HY, You SC, Lin H.

Cancer Res. 2016 Dec 1;76(23):6888-6900. Erratum in: Cancer Res. 2017 Mar 15;77(6):1504.

PMID:
27909065
8.

Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy.

Huang WY, Lin JN, Hsieh JT, Chou SC, Lai CH, Yun EJ, Lo UG, Pong RC, Lin JH, Lin YH.

ACS Appl Mater Interfaces. 2016 Nov 16;8(45):30722-30734. Epub 2016 Nov 7.

PMID:
27786455
9.

Clinical and Imaging Outcomes up to 1 Year Following Balloon Angioplasty for Isolated Penile Artery Stenoses in Patients With Erectile Dysfunction: The PERFECT-2 Study.

Wang TD, Lee WJ, Yang SC, Lin PC, Tai HC, Liu SP, Huang CH, Chen WJ, Chen MF, Hsieh JT.

J Endovasc Ther. 2016 Dec;23(6):867-877. Epub 2016 Sep 14.

PMID:
27629440
10.

Tumor suppressor protein DAB2IP participates in chromosomal stability maintenance through activating spindle assembly checkpoint and stabilizing kinetochore-microtubule attachments.

Yu L, Shang ZF, Abdisalaam S, Lee KJ, Gupta A, Hsieh JT, Asaithamby A, Chen BP, Saha D.

Nucleic Acids Res. 2016 Oct 14;44(18):8842-8854. Epub 2016 Aug 27.

11.

DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein.

Wang B, Huang J, Zhou J, Hui K, Xu S, Fan J, Li L, Wang X, Hsieh JT, He D, Wu K.

Cell Signal. 2016 Nov;28(11):1623-30. doi: 10.1016/j.cellsig.2016.07.011. Epub 2016 Jul 27.

PMID:
27476001
12.

Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues.

Chen W, Zhou J, Wu K, Huang J, Ding Y, Yun EJ, Wang B, Ding C, Hernandez E, Santoyo J, Chen H, Lin H, Sagalowsky A, He D, Zhou J, Hsieh JT.

Oncotarget. 2016 Aug 30;7(35):56842-56854. doi: 10.18632/oncotarget.10863.

13.

miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion.

Huang J, Wang B, Hui K, Zeng J, Fan J, Wang X, Hsieh JT, He D, Wu K.

Oncol Rep. 2016 Sep;36(3):1693-701. doi: 10.3892/or.2016.4940. Epub 2016 Jul 15.

PMID:
27430302
14.

Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.

Kumar A, Mastren T, Wang B, Hsieh JT, Hao G, Sun X.

Bioconjug Chem. 2016 Jul 20;27(7):1681-9. doi: 10.1021/acs.bioconjchem.6b00222. Epub 2016 Jun 15.

PMID:
27248781
15.

Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.

Wang ZR, Wei JH, Zhou JC, Haddad A, Zhao LY, Kapur P, Wu KJ, Wang B, Yu YH, Liao B, He DL, Chen W, Margulis V, Hsieh JT, Luo JH.

Oncotarget. 2016 May 24;7(21):31508-19. doi: 10.18632/oncotarget.8971.

16.

Comparison of Gender Differences in Intracerebral Hemorrhage in a Multi-Ethnic Asian Population.

Hsieh JT, Ang BT, Ng YP, Allen JC, King NK.

PLoS One. 2016 Apr 6;11(4):e0152945. doi: 10.1371/journal.pone.0152945. eCollection 2016.

17.

Molecular Mechanisms and Potential Clinical Applications of Campylobacter jejuni Cytolethal Distending Toxin.

Lai CK, Chen YA, Lin CJ, Lin HJ, Kao MC, Huang MZ, Lin YH, Chiang-Ni C, Chen CJ, Lo UG, Lin LC, Lin H, Hsieh JT, Lai CH.

Front Cell Infect Microbiol. 2016 Feb 9;6:9. doi: 10.3389/fcimb.2016.00009. eCollection 2016. Review.

18.

Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, Yang J, Xiao G, Cha TL, Wu HC, Wu D, Margulis V, Lotan Y, Brugarolas J, He D, Hsieh JT.

Oncogene. 2016 Sep 1;35(35):4663-74. doi: 10.1038/onc.2016.4. Epub 2016 Feb 15.

PMID:
26876207
19.

Epigallocatechin Gallate Attenuates Partial Bladder Outlet Obstruction-induced Bladder Injury via Suppression of Endoplasmic Reticulum Stress-related Apoptosis-In Vivo Study.

Hsieh JT, Kuo KL, Liu SH, Shi CS, Chang HC, Lin WC, Chou CT, Hsu CH, Liao SM, Wang ZH, Li CC, Huang KH.

Urology. 2016 May;91:242.e1-9. doi: 10.1016/j.urology.2015.12.020. Epub 2016 Jan 25.

PMID:
26820120
20.

MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study.

Lin WC, Kuo KL, Shi CS, Wu JT, Hsieh JT, Chang HC, Liao SM, Chou CT, Chiang CK, Chiu WS, Chiu TY, Pu YS, Ho IL, Wang ZH, Chang SC, Liu SH, Jeng YM, Huang KH.

Am J Cancer Res. 2015 Oct 15;5(11):3350-62. eCollection 2015.

Supplemental Content

Loading ...
Support Center